JP2020125349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020125349A5 JP2020125349A5 JP2020081156A JP2020081156A JP2020125349A5 JP 2020125349 A5 JP2020125349 A5 JP 2020125349A5 JP 2020081156 A JP2020081156 A JP 2020081156A JP 2020081156 A JP2020081156 A JP 2020081156A JP 2020125349 A5 JP2020125349 A5 JP 2020125349A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- cell
- cancer
- leukemia
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 201000011510 cancer Diseases 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 206010025323 Lymphomas Diseases 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 239000002955 immunomodulating agent Substances 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 208000017604 Hodgkin disease Diseases 0.000 claims 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims 4
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 210000004907 gland Anatomy 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 4
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 4
- 210000000214 mouth Anatomy 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 210000001635 urinary tract Anatomy 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 3
- 230000000259 anti-tumor effect Effects 0.000 claims 3
- 238000002659 cell therapy Methods 0.000 claims 3
- 208000015114 central nervous system disease Diseases 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 230000009933 reproductive health Effects 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000012609 Cowden disease Diseases 0.000 claims 2
- 201000002847 Cowden syndrome Diseases 0.000 claims 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 2
- 208000002927 Hamartoma Diseases 0.000 claims 2
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 2
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 201000004458 Myoma Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims 2
- 208000007531 Proteus syndrome Diseases 0.000 claims 2
- 208000014841 Proteus-like syndrome Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 2
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 210000000436 anus Anatomy 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 201000000053 blastoma Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000000621 bronchi Anatomy 0.000 claims 2
- 210000005252 bulbus oculi Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000022131 cell cycle Effects 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000008184 embryoma Diseases 0.000 claims 2
- 210000000416 exudates and transudate Anatomy 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002518 glial effect Effects 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 201000002222 hemangioblastoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000000366 juvenile effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000000088 lip Anatomy 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 201000006894 monocytic leukemia Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 210000003928 nasal cavity Anatomy 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 claims 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 230000000849 parathyroid Effects 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 210000003635 pituitary gland Anatomy 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000004500 stellate cell Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- XEIVCDDCSGGZSG-UHFFFAOYSA-N 7-[3-[(3-formylphenoxy)methyl]-1,5-dimethylpyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1H-indole-2-carboxylic acid Chemical compound Cc1c(c(COc2cccc(C=O)c2)nn1C)-c1cccc2c(CCCOc3cccc4ccccc34)c([nH]c12)C(O)=O XEIVCDDCSGGZSG-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000027626 Neurocognitive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010000210 abortion Diseases 0.000 claims 1
- 231100000176 abortion Toxicity 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 125000002560 nitrile group Chemical group 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000861 pro-apoptotic effect Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002476 tumorcidal effect Effects 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1419570.5 | 2014-11-03 | ||
| GBGB1419570.5A GB201419570D0 (en) | 2014-11-03 | 2014-11-03 | Pharmaceutical compound |
| GB1507883.5 | 2015-05-08 | ||
| GBGB1507883.5A GB201507883D0 (en) | 2015-05-08 | 2015-05-08 | Pharmaceutical compound |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542315A Division JP6701214B2 (ja) | 2014-11-03 | 2015-11-02 | 医薬化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020125349A JP2020125349A (ja) | 2020-08-20 |
| JP2020125349A5 true JP2020125349A5 (https=) | 2020-10-15 |
| JP6994538B2 JP6994538B2 (ja) | 2022-01-14 |
Family
ID=54476948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542315A Active JP6701214B2 (ja) | 2014-11-03 | 2015-11-02 | 医薬化合物 |
| JP2020081156A Active JP6994538B2 (ja) | 2014-11-03 | 2020-05-01 | 医薬化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542315A Active JP6701214B2 (ja) | 2014-11-03 | 2015-11-02 | 医薬化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10590086B2 (https=) |
| EP (1) | EP3215156B1 (https=) |
| JP (2) | JP6701214B2 (https=) |
| KR (1) | KR102602947B1 (https=) |
| CN (2) | CN107108556B (https=) |
| AU (1) | AU2015341913B2 (https=) |
| CA (1) | CA2965741C (https=) |
| ES (1) | ES3055013T3 (https=) |
| MX (1) | MX390081B (https=) |
| RU (1) | RU2719446C2 (https=) |
| WO (1) | WO2016071293A2 (https=) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| WO2016071293A2 (en) * | 2014-11-03 | 2016-05-12 | Iomet Pharma Ltd | Pharmaceutical compound |
| JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| PT3889145T (pt) | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| CN107619392B (zh) * | 2016-07-15 | 2021-01-01 | 西华大学 | 1h-吲唑-4-醚类化合物及其作为ido抑制剂的用途 |
| WO2017133258A1 (zh) * | 2016-02-04 | 2017-08-10 | 西华大学 | 1h-吲唑类衍生物及其作为ido抑制剂的用途 |
| CN107033087B (zh) * | 2016-02-04 | 2020-09-04 | 西华大学 | 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途 |
| CN107840826B (zh) * | 2016-09-19 | 2021-07-09 | 西华大学 | 1h-吲唑类衍生物及其作为ido抑制剂的用途 |
| JP6948345B2 (ja) | 2016-04-29 | 2021-10-13 | イオメット ファーマ リミテッド | インドールアミン２，３−ジオキシゲナーゼ及び／又はトリプトファン−２，３−ジオキシゲナーゼの阻害薬としての新規置換イミダゾピリジン化合物 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN107556244B (zh) * | 2016-07-01 | 2021-09-03 | 上海迪诺医药科技有限公司 | 并环化合物、其药物组合物及应用 |
| EP3269714A1 (en) | 2016-07-13 | 2018-01-17 | Netherlands Translational Research Center B.V. | Inhibitors of tryptophan 2,3-dioxygenase |
| CN107674029A (zh) * | 2016-08-02 | 2018-02-09 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| EP4198031A1 (en) | 2016-08-08 | 2023-06-21 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| WO2018036414A1 (zh) * | 2016-08-23 | 2018-03-01 | 北京诺诚健华医药科技有限公司 | 稠杂环类衍生物、其制备方法及其在医学上的应用 |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| US10882856B2 (en) | 2016-09-24 | 2021-01-05 | Beigene, Ltd. | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases |
| EP3532466A1 (en) | 2016-10-26 | 2019-09-04 | E-Therapeutics plc | Modulators of hedgehog (hh) signalling pathway |
| CA3047002A1 (en) | 2017-01-17 | 2018-07-26 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| KR102294129B1 (ko) * | 2017-03-16 | 2021-08-27 | 국제약품 주식회사 | N-벤질-n-페녹시카르보닐-페닐설폰아마이드 유도체 및 그를 포함하는 약제학적 조성물 |
| CN108689938B (zh) * | 2017-04-10 | 2021-07-30 | 西华大学 | 多取代的吲唑类化合物及其作为ido抑制剂的用途 |
| CN108689937B (zh) * | 2017-04-10 | 2021-09-17 | 西华大学 | 吲唑类化合物及其在制备ido抑制剂类药物上的用途 |
| CN108689936B (zh) * | 2017-04-10 | 2021-09-10 | 西华大学 | 含氮取代基的吲唑类化合物及其作为ido抑制剂的用途 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELIN BINDING PROTEINS |
| JP2020522495A (ja) | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| EP3645538A1 (en) * | 2017-06-28 | 2020-05-06 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| AU2018312349A1 (en) | 2017-08-01 | 2020-02-06 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| JP7306634B2 (ja) | 2017-10-19 | 2023-07-11 | 一般社団法人ファルマバレープロジェクト支援機構 | Ｉｄｏ／ｔｄｏ阻害剤 |
| KR20200074971A (ko) * | 2017-10-19 | 2020-06-25 | 제이에스 이노팜 (상하이) 리미티드 | 헤테로사이클릭 화합물, 헤테로사이클릭 화합물을 포함하는 조성물 및 그의 사용 방법 |
| US11759461B2 (en) | 2017-10-30 | 2023-09-19 | The Scripps Research Institute | Small molecule inhibitors of cancer stem cells and mesenchymal cancer types |
| CN111386114A (zh) | 2017-11-25 | 2020-07-07 | 百济神州有限公司 | 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑 |
| TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗ｒｓｖ活性之吡唑并嘧啶 |
| CN108586378B (zh) | 2018-01-22 | 2020-06-19 | 南京华威医药科技集团有限公司 | 吲哚胺2,3-双加氧化酶抑制剂及其制备方法和用途 |
| BR112020015396A2 (pt) | 2018-01-29 | 2020-12-08 | Merck Patent Gmbh | Inididores de gcn2 e usos dos mesmos |
| JP7229257B2 (ja) | 2018-01-29 | 2023-02-28 | メルク パテント ゲーエムベーハー | Ｇｃｎ２阻害剤およびその使用 |
| SG11202006141RA (en) | 2018-01-31 | 2020-07-29 | Janssen Sciences Ireland Unlimited Co | Cycloalkyl substituted pyrazolopyrimidines having activity against rsv |
| CN110156674A (zh) * | 2018-02-13 | 2019-08-23 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| EP3768666A1 (en) * | 2018-03-20 | 2021-01-27 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| US11708369B2 (en) | 2018-04-23 | 2023-07-25 | Janssen Sciences Ireland Unlimited Company | Heteroaromatic compounds having activity against RSV |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| EP3873464B1 (en) * | 2018-11-01 | 2025-07-30 | Merck Sharp & Dohme LLC | Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors |
| CN111285808B (zh) * | 2018-12-07 | 2023-06-23 | 西华大学 | 4位芳杂环取代的吲唑类化合物及其作为ido/tdo双重抑制剂的用途 |
| CN113498352A (zh) | 2019-01-23 | 2021-10-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪 |
| CN111689901A (zh) * | 2019-03-13 | 2020-09-22 | 西华大学 | 一类具有tdo、ido1双重抑制活性的化合物及制备治疗神经退行性疾病药物的用途 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US12358879B2 (en) | 2019-10-18 | 2025-07-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP2023504623A (ja) * | 2019-12-04 | 2023-02-06 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ｈｉｆ－２アルファの阻害剤 |
| US20220396577A1 (en) * | 2019-12-17 | 2022-12-15 | Merck Sharp & Dohme Llc | Novel substituted 1,3-8-triazaspiro[4,5] decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors |
| US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
| KR20230026479A (ko) | 2020-06-22 | 2023-02-24 | 에프. 호프만-라 로슈 아게 | 설폰 유도체 |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| CN114057641B (zh) * | 2020-08-07 | 2025-02-18 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用 |
| JP7545570B2 (ja) | 2020-08-14 | 2024-09-04 | ノバルティス アーゲー | ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用 |
| AU2021331624A1 (en) * | 2020-08-31 | 2023-05-04 | Visus Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| JP2023549738A (ja) | 2020-10-30 | 2023-11-29 | １シーバイオ， インコーポレイテッド | エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼ－１（ｅｎｐｐ１）阻害物質及びそれらの使用 |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| MX2023010371A (es) | 2021-03-05 | 2024-02-12 | Univ Basel | Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb. |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| WO2022226166A1 (en) * | 2021-04-22 | 2022-10-27 | Protego Biopharma, Inc. | Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| JP2025508076A (ja) | 2022-03-08 | 2025-03-21 | アレンティス・セラピューティクス・アクチェンゲゼルシャフト | Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用 |
| WO2024073658A1 (en) * | 2022-09-30 | 2024-04-04 | Genentech, Inc. | Hydantoin modulators of cholesterol biosynthesis and their use for promoting remyelination |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| WO2025201397A1 (en) * | 2024-03-27 | 2025-10-02 | Insilico Medicine Ip Limited | Tead inhibitors and methods of uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US685109A (en) * | 1901-08-15 | 1901-10-22 | Joseph P Cornelius | Car-fender. |
| US1540442A (en) * | 1923-03-12 | 1925-06-02 | Leo T Ward | Ventilating window lock |
| AU6246198A (en) * | 1997-02-18 | 1998-09-08 | American Home Products Corporation | 4-aminoethoxyindazole derivatives |
| EP0999208A4 (en) * | 1997-05-30 | 2001-08-08 | Meiji Seika Kaisha | NITROGEN-BASED HETEROCYCLIC COMPOUNDS AND MEDICINES FOR TREATING HYPERLIPEMIA THAT CONTAIN THEM |
| ES2244438T3 (es) | 1999-05-24 | 2005-12-16 | Mitsubishi Pharma Corporation | Compuestos de fenoxipropilamina. |
| AU2001262150A1 (en) * | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(nitrogen-heterocyclic)pyrimidone derivatives |
| JP4184077B2 (ja) * | 2000-11-02 | 2008-11-19 | ワイス | ５−ヒドロキシトリプトアミン−６リガンドとしての１−アリールまたは１−アルキルスルホニル−ヘテロシクリルベンザゾール |
| US7034029B2 (en) * | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| US6864255B2 (en) * | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
| WO2002100833A1 (en) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Rho KINASE INHIBITORS |
| FR2836914B1 (fr) * | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| EP1592683A2 (en) * | 2003-02-14 | 2005-11-09 | Wyeth | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
| WO2005039564A1 (en) | 2003-10-02 | 2005-05-06 | Vertex Pharmaceuticals Incorporated | Phthalimide compounds useful as protein kinase inhibitors |
| US20050267096A1 (en) * | 2004-05-26 | 2005-12-01 | Pfizer Inc | New indazole and indolone derivatives and their use pharmaceuticals |
| JP4093588B2 (ja) * | 2004-05-26 | 2008-06-04 | ファイザー・インク | 新規インダゾール及びインドロン誘導体及び調合剤としてのそれらの使用 |
| EP1866298A2 (en) * | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| PE20070521A1 (es) * | 2005-09-23 | 2007-07-13 | Schering Corp | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a |
| JP2007145786A (ja) * | 2005-11-30 | 2007-06-14 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| US7939557B2 (en) * | 2006-04-20 | 2011-05-10 | Nova Southeastern University | Vascular endothelial receptor specific inhibitors |
| JP2008208074A (ja) * | 2007-02-27 | 2008-09-11 | Toray Ind Inc | ピラジン誘導体を有効成分とする抗がん剤 |
| MX2009012471A (es) * | 2007-05-24 | 2010-02-24 | Memory Pharm Corp | Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6. |
| WO2009147189A1 (en) * | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| JP2013512880A (ja) * | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体 |
| WO2012044090A2 (ko) * | 2010-09-29 | 2012-04-05 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| WO2013130855A1 (en) * | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| US20150051202A1 (en) | 2012-03-07 | 2015-02-19 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| KR20150126623A (ko) | 2013-03-14 | 2015-11-12 | 뉴링크 제네틱스 코퍼레이션 | 트립토판 대사로 인한 면역억제의 억제제로서의 삼환식 화합물 |
| WO2016071293A2 (en) | 2014-11-03 | 2016-05-12 | Iomet Pharma Ltd | Pharmaceutical compound |
-
2015
- 2015-11-02 WO PCT/EP2015/075486 patent/WO2016071293A2/en not_active Ceased
- 2015-11-02 MX MX2017005719A patent/MX390081B/es unknown
- 2015-11-02 ES ES15790910T patent/ES3055013T3/es active Active
- 2015-11-02 EP EP15790910.2A patent/EP3215156B1/en active Active
- 2015-11-02 US US15/524,142 patent/US10590086B2/en active Active
- 2015-11-02 RU RU2017118160A patent/RU2719446C2/ru active
- 2015-11-02 CN CN201580072167.1A patent/CN107108556B/zh active Active
- 2015-11-02 KR KR1020177014762A patent/KR102602947B1/ko active Active
- 2015-11-02 JP JP2017542315A patent/JP6701214B2/ja active Active
- 2015-11-02 CN CN202010871093.0A patent/CN111943890B/zh active Active
- 2015-11-02 AU AU2015341913A patent/AU2015341913B2/en active Active
- 2015-11-02 CA CA2965741A patent/CA2965741C/en active Active
-
2020
- 2020-02-03 US US16/780,349 patent/US11130738B2/en active Active
- 2020-05-01 JP JP2020081156A patent/JP6994538B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020125349A5 (https=) | ||
| JP2021522249A5 (https=) | ||
| CN107108556B (zh) | 药用化合物 | |
| JP2021534168A5 (https=) | ||
| JP2020504716A5 (https=) | ||
| JP2021534158A5 (https=) | ||
| RU2750727C9 (ru) | Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там | |
| BR112020013672A2 (pt) | compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia | |
| JP2023506787A5 (https=) | ||
| RU2018113339A (ru) | Фармацевтическое соединение | |
| WO2013104263A1 (zh) | 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用 | |
| WO2007143483A2 (en) | Combination of pazopanib and lapatinib for treating cancer | |
| JP2022512826A (ja) | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 | |
| CN117062819A (zh) | 多环化合物及其用途 | |
| JP7296070B2 (ja) | がん免疫療法アジュバント | |
| CN110461836B (zh) | 一种选择性抑制激酶化合物及其用途 | |
| JP2014532751A5 (https=) | ||
| JP2019522681A5 (https=) | ||
| RU2018119935A (ru) | 1,4-дикарбонилпиперидильные производные | |
| CN114599360A (zh) | 4-氨基-咪唑并喹啉化合物及其用途 | |
| JP2005504790A (ja) | 癌を治療するための３−グリオキシリルアミドインドール | |
| US20090005406A1 (en) | Cancer Treatment Method | |
| JP2018528949A5 (https=) | ||
| JP2021513963A (ja) | 異常増殖性疾患を治療するための薬剤および方法 | |
| CA3116137A1 (en) | Tlr7 agonist for treating colorectal cancer and pharmaceutical combination thereof |